For people with haemophilia
A, finding treatments that are effective at preventing bleeding episodes long-term is essential.
Elocta is a long-acting recombinant factor VIII Fc fusion protein product candidate for people with haemophilia
The Newcastle Haemophilia
Centre is a regional centre, which means it takes patients from the whole of the northern region, from Berwick in the north, across to Cumbria in the west and down to Teesside and North Yorkshire.
Early proof-of-concept studies have shown that gene therapy can be a cost-effective alternative to treat haemophilia
generally transmits at birth from an affected father to daughter, who then becomes a carrier of the haemophilia
cells who is at higher risk of passing the defective gene on to her children.
Dr Jayson Stoffman, Assistant Professor, Department of Paediatrics and Child HealthancerCare Manitoba, who is participating in the symposium, said: "With the support of the World Federation of Haemophilia
, the Paediatric Bleeding Disorders Program at Winnipeg, Canada is excited to be partnered with the Haemophilia
In this context, the National Institute of Immunohaematology (NIIH) at Mumbai has been playing a central role for haemophilia
care and research in India.
Phase 3 Clinical Trial Pipeline Insights
The World Federation of Haemophilia
(WFH) is a non-profit organization founded in 1963 with the aim of improving global haemophilia
care to all people with haemophilia
, wherever they live.
Licensing activities and partnerships in the haemophilia
drug market is thoroughly covered by company and licensee with the deal summary.
is approved by the US Food and Drug Administration (October 2013) and the European Medicines Agency (November 2013) for the treatment and prophylaxis of bleeding in patients with haemophilia
An extensive literature review to assess the existing literature and establish gaps in knowledge, published in Haemophilia
Develop business strategies by understanding the trends shaping and driving the global haemophilia
turoctocog alfa), the first new rFVIII molecule in over a decade, which shows that it provides long-term reduction from bleeding in people with haemophilia
A when used as a preventative treatment.
Results recently presented at the 5th Annual Congress of the European Association for Haemophilia
and Allied Disorders demonstrated that IB1001 provided effective surgical hemostasis in study participants with hemophilia B undergoing major surgical procedures.